Evidence map›Paper›PMID 32519274›Full record

ArticleHormones & cancer2020

Estrogen Receptor Positive and Progesterone Receptor Negative Breast Cancer: the Role of Hormone Therapy.

Robert Dembinski, Vishnu Prasath, Carisa Bohnak, Charalampos Siotos, Mohamad E Sebai, Kevin Psoter, Faiz Gani, Joe Canner, Melissa S Camp, Armina Azizi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hormones & cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Robert DembinskiDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Vishnu PrasathDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Carisa BohnakDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Charalampos SiotosDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Mohamad E SebaiDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Kevin PsoterDepartment of Pediatrics, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Faiz GaniDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Joe CannerDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Melissa S CampDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Armina AziziDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Lisa JacobsDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Mehran HabibiDepartment of Surgery, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Bayview Campus, Building A, 5th Floor, 4940 Eastern Avenue, Baltimore, MD, 21224, USA. mhabibi2@jhmi.edu.ORCID 0000-0003-2944-4388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ER+/PR- (estrogen receptor positive and progesterone receptor negative) tumors constitute only a small portion of the breast cancer population. Patients with ER+/PR- tumors, however, are characterized by worse survival compared to patients with ER+/PR+ (estrogen receptor positive and progesterone receptor positive) tumors. Controversy exists regarding the efficacy of hormone blocking therapy for patients with ER+/PR- tumors. The NCDB was queried between 2004 and 2015, and patients with invasive ER+/PR- tumors were identified. We employed univariate Cox proportional hazards to compare outcomes among patients that did or did not receive hormone blocking therapy. We identified 138,398 patients with invasive ER+/PR- tumors, 32,044 (23%) of whom did not receive hormone blocking therapy. The reasons for not receiving hormone blocking therapy included contraindications to treatment, death, patient refusal, and unknown. There were no significant differences in race, income quartile, or education quartile between patients who did and did not receive hormone blocking therapy. Patients who did not receive hormone blocking therapy underwent surgical assessment of the axilla more frequently than those who did receive hormone therapy. Our analysis demonstrated that hormone blocking therapy administration was associated with increased overall survival for up to 10 years of follow up (HR: 0.58; 95% CI: 0.56-0.59, p < 0.001). Hormone blocking therapy may be associated with increased survival for breast cancer patients with ER+/PR- tumors. Although this benefit may last for years after completion of the course, up to 25% of patients do not receive this treatment. Strategies to increase the utilization and adherence to hormone blocking therapy regimens may improve patient survival outcomes.

Indexed as

AgedBreast NeoplasmsFemaleHormone Replacement TherapyHumansMiddle AgedReceptors, EstrogenReceptors, ProgesteroneReceptors, EstrogenReceptors, ProgesteroneBreast cancerER+/−Hormone therapyPR+/−

Identifiers

PMID32519274
PMCPMC10355243

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.